http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010514696-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 2007-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010514696-A |
| titleOfInvention | Reduction of cardiovascular symptoms |
| abstract | The present application treats patients with cardiac ion channel dysfunction suffering from one or more cardiovascular diseases to reduce the arrhythmogenic effects of drugs and / or conditions that reduce or inhibit I Kr A method is disclosed. In one aspect, the present invention comprises administration of ranolazine therapeutically effective amount, related to a method of treating patients with dysfunction of the ion channels of the heart, wherein the reducing or inhibiting I Kr state, arrhythmia Including abnormalities of ventricular repolarization and disturbances of relaxation of ventricular contractions. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9338574-B2 |
| priorityDate | 2006-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.